Focus: Merck could keep its patent edge by shifting Keytruda …
WEBDec 2, 2022 · U.S. drugmaker Merck & Co hopes to patent a new formulation of its $20 billion cancer immunotherapy Keytruda that can be injected under the skin, allowing it to protect its best-selling drug from...
The top 15 blockbuster patent expirations coming this decade
WEBLooking out over the next decade, some of the biggest drugs in the industry will tumble off the patent cliff, putting pharma giants in the hot seat as investors clamor for their next blockbuster.
WEBMay 6, 2021 · KEY FINDINGS: Keytruda has 129 patent applications; to date, 53 patents have been granted. 50% of the patent applications on Keytruda were filed after its first FDA approval. 74% of patent applications cover the different indications and formulations of the drug and not the key antibody.
Merck keeps deal focus with Keytruda patent cliff on horizon
WEBFeb 1, 2024 · Merck & Co. plans to continue seeking out multibillion-dollar biotechnology deals to supplement its own drug research as it prepares for its dominant cancer immunotherapy Keytruda to lose patent protection later this decade.
Merck on deals hunt as patent cliff looms for top cancer drug
WEBOct 6, 2021 · Merck has filed 129 patents linked to Keytruda, which could extend the period of exclusivity to 2036 and beyond, according to research by the Initiative for Medicines, Access & Knowledge, a...
September 2024 - When do the KEYTRUDA patents expire
WEB5 days ago · These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company. General brand-side disclosures.
Keytruda beaten by Summit’s bispecific in NSCLC - Yahoo Finance
WEB2 days ago · Merck should not just be worried about Keytruda’s patent expiry in 2028, but also look out for competition from upcoming innovative therapies. "Keytruda beaten by Summit’s bispecific in NSCLC ...
Merck Announces Settlement and License Agreement Resolving KEYTRUDA …
WEBJan 1, 2017 · Ono Pharmaceutical Co., Ltd., resolving the worldwide patent infringement litigation related to the use of an anti-PD-1 antibody for the treatment of cancer, such as KEYTRUDA ® (pembrolizumab).
Keytruda remains Merck & Co’s biggest 2023 success story as patent …
WEBFeb 1, 2024 · The PD-1 inhibitor Keytruda, which is approved to treat 17 tumour types and other cancers based on the presence of certain genetic alterations, generated $25bn sales in 2023, a 19% increase compared to $20.9bn in 2022.
Merck Scores Major Drug Approval, Easing Pain From Keytruda Patent ...
WEBThat is when patents expire on Merck’s cancer medicine Keytruda, exposing the drug to competition from biosimilar versions. Keytruda sales were $25 billion in 2023, and accounted for 41.6%...